Abstract
Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.
Original language | English (US) |
---|---|
Pages (from-to) | 433-445 |
Number of pages | 13 |
Journal | Expert Review of Hematology |
Volume | 9 |
Issue number | 5 |
DOIs | |
State | Published - May 3 2016 |
Externally published | Yes |
Keywords
- AML
- clinical trials
- molecular therapy
- monoclonal antibodies
- multikinase inhibitors
ASJC Scopus subject areas
- Hematology